Quantiphi and Moffitt Cancer Center enter into a strategic partnership to co-develop a high-precision Machine Learning-enabled intelligent pathology solution: an end-to-end solution facilitating how pathologists screen and identify cells in patients’ biopsy samples.
MARLBOROUGH, Mass. — Quantiphi, an AI-first digital engineering company, announced its latest partnership with Moffitt Cancer Center in co-developing a digital pathology solution to quickly and efficiently assist in the detection and diagnosis of common hematologic cancers including lymphoma, myeloma, and leukemia. The intelligent solution is designed to harness the true power of machine learning (ML) and help healthcare professionals around the globe accurately quantify and classify cellular constituents in bone marrow biopsies with the aim of optimizing diagnostic efficiencies in clinical care.
Moffitt Cancer Center is the only NCI comprehensive cancer center based in Florida and one of only 30 leading cancer centers in the U.S. participating in the National Comprehensive Cancer Network. Moffitt is at the forefront of cancer centers worldwide striving to transform cancer care through service, science, and strategic partnerships.
“We’re delighted to partner with Moffitt on this exciting initiative,” said Bruno Nardone, Global Head of Healthcare and Life Sciences at Quantiphi. “This collaboration effectively supports our vision of a healthcare system that focuses more on early diagnosis, treatment, and prevention of cancer. The partnership will supply us with profound insights to support the development of a purpose-built solution that enables forward-looking HCOs to take full advantage of technologies like ML and Computer Vision. We look forward to helping physicians around the globe harness cutting-edge innovation and help reimagine their cancer care approach.”
Quantiphi has been working on developments in the digital pathology space and is thrilled to utilize its in-depth knowledge and deep expertise in ML and Computer Vision combined with Moffitt’s healthcare capabilities, to bring forward a groundbreaking solution that can extract pertinent insights, enhance clinical outcomes, and create a safer world.
“The latest advances in healthcare technologies, such as AI, ML, and Computer Vision, are shaping the future of health. As a result, physicians rely on partnerships such as Moffitt and Quantiphi to speed up cancer diagnosis and elevate the patient experience,” said Dr. Mohammad Hussaini, MD at Moffitt Cancer Center. “We are thrilled to have partnered with Quantiphi and look forward to paving a new and improved path for healthcare institutions worldwide to leverage new-age pathology solutions for facilitating timely and accurate cancer diagnosis.”
Together, Quantiphi and Moffitt plan to develop a Cell Classification solution that leverages an intelligent ML model to perform nucleated differential cell counts for at least 14 different classes of cells based on scanned images of bone marrow biopsies from patients with lymphoma, leukemia, myeloma as well as those with myelodysplastic syndrome, and myeloproliferative neoplasms (MPN). Quantiphi and Moffitt will work collaboratively on the solution with the combined goal of facilitating physicians worldwide to efficiently upload scanned images of human tissue biopsies and generate quantitative classifications of cell distribution in each case with ease.
Quantiphi’s expertise, led by its new-age digital engineering approach that leverages disruptive technologies like AI and ML, will enable the pathology solution to yield a higher degree of efficiency and effectiveness in capturing results. This will drive a quicker turnaround time in cancer cell diagnosis and reduce costs of care as early diagnosis improves cancer outcomes by providing care at the earliest possible stage.
Quantiphi is an award-winning AI-first digital engineering company driven by the desire to solve transformational problems at the heart of the business. Quantiphi solves the toughest and complex business problems by combining deep industry experience, disciplined cloud, data-engineering practices, and cutting-edge artificial intelligence research to achieve quantifiable business impact at unprecedented speed. We are passionate about our customers and obsessed with problem-solving to make products smarter, customer experiences frictionless, processes autonomous and businesses safer by detecting risks, threats, and anomalies. Together with partners and customers, we embark on a data and AI-led transformation journey that delivers impactful and measurable results. For more on Quantiphi’s capabilities, visit www.quantiphi.com